On the Record · Lakefront Biotherapeutics
Lakefront Biotherapeutics subsidiaries, as it lists them
The subsidiaries Lakefront Biotherapeutics lists in its latest annual report, with the jurisdiction of each, linked to the filing.
Subsidiaries it lists
| Subsidiary | Jurisdiction |
|---|---|
| Galapagos B.V. | The Netherlands |
| Galapagos U.K. Ltd | United Kingdom |
| Galapagos SASU | France |
| Galapagos GmbH | Switzerland |
| Galapagos Real Estate Netherlands B.V. | The Netherlands |
| GLPG US Holding Inc. (formerly Galapagos, Inc.) | United States |
| GLPG US Inc. (formerly AboundBio, Inc.) | United States |
| Xenometrix, Inc. (in liquidation) | United States |
| Galapagos Holding Pte. Ltd. | Singapore |
| Galapagos (Shanghai) Bioscience Co. Ltd. | China |
| Galapagos Cell Therapeutics NV | Belgium |
| Lakefront Biotherapeutics, Inc. | United States |
From the subsidiary exhibit of the 20-F for 2025. Companies must list their significant subsidiaries there and may leave out smaller ones, so this is the company’s own list, not every entity it owns.
Read from Lakefront Biotherapeutics’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-03-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.